Five years ago — before the pandemic — Pfizer’s head of research and development, Mikael Dolsten, told STAT he kept a chess set in his office that he got as a gift from a former CEO of the company. It was a memento delivered to Dolsten after he cautioned his boss that research and development was a long process, like a chess match, not something that would happen quickly.
“I told him that, look, it’s not just one investment, it is like playing chess,’’ Dolsten said. “You need to have a picture of the entire opening game, win the middle game, and be really good in the endgame.”
On Tuesday, Dolsten reached the endgame.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect